SARS-CoV-2 Outbreak in Wuhan {#sec1}
============================

In December 2019, an outbreak of pneumonia of an unknown cause was reported in Wuhan, in Hubei province, China. It was speculated that the first patient caught the infection from a seafood market that also traded wild animals. The causing agent was quickly identified as a novel coronavirus (CoV). The CoV responsible for the outbreak is now called SARS-CoV-2. The respiratory illness caused by SARS-CoV-2 is called COVID-19. The symptoms of the SARS-CoV-2 infection range from asymptomatic to mild to severe to death.[@bib1] It soon became clear that person-to-person transmission was also occurring, as was the case with the previous human CoV. In an unprecedented documented speed, the SARS-CoV-2 travels around the globe, and as of May 15^th^ led to \>4.5 million infections and 300,000 fatalities. Based on the previous experience with the SARS-CoV outbreak at the beginning of this century, very stringent measures were taken by the Chinese government, and several multimillion-inhabitant cities were isolated and put under quarantine in order to slow the pandemic spread. Different hosts of the SARS-CoV-2 are proposed, including snails, bats, and pangolins.[@bib2]

CoVs are a large family of zoonotic viruses and their outbreaks are common to humans, although major outbreaks have been experienced in animals, especially in cattle. Under the electron microscope, they exhibit formations that are reminiscent of the solar corona. The common cold is often caused by human CoVs. They are single-stranded enveloped positive RNA viruses and stand out because of their rather large genome. As with viruses in general, the structure is rather simple. SARS-CoV-2 is generally less pathogenic than SARS-CoV, much less pathogenic than the Middle East respiratory syndrome MERS-CoV, but more pathogenic than practically harmless HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63. The reported case-fatality rate of COVID-19 is ≤3% and is thus rather low as compared with SARS (30%, [Table 1](#tbl1){ref-type="table"} ). However, the transmission rate (TR) (number of newly infected people per infected person) of 2.5 to 3 is high and accounts for the danger of the current pandemic. For comparison, the TR of the yearly common cold is less than 1.4.Table 1Some Data to the New and Previous Epi- and PandemicsPandemic (Causing Agent) TimeTransmissionMortalityNo. of Infection CasesNo. of Death CasesBlack death (Yersinia pestis)\
14^th^ centuryN/AN/AN/A\>50 millionSpanish flu (Influenza virus)\
1918--1920N/A10%--20%500 million40--100 millionSARS (SARS-CoV)\
2002--2003N/A30%8,000800Covid-19 (SARS-CoV-2)\
Since November 2019\>2%≤3%\>4,500,000\>300,000Swine flu (H1N1 virus)\
2009--2010N/A0.01%--0.1%700--1,400 million50,000--575,000

Advice guidelines for diagnosis and treatment of SARS-CoV-2 infected pneumonia have been shared rapidly.[@bib3]

What are the issues and chances for a rapid approval of a new medicine to treat COVID-19? In principle, there are several potential strategies to pharmacologically fight COVID-19: vaccines, monoclonal antibodies, oligonucleotide-based therapies, peptides, interferon therapies, small-molecule drugs, or natural medicines (e.g., traditional Chinese medicine \[TCM\]). The timelines for *de novo* development of a small-molecule drug are historically \>6--7 years, and in the best case less than 2 years. Vaccines can be developed much faster, but rapid development in the range of 1--2 years is very challenging. Antibodies to support the body's immune system are also a strategy to combat viral diseases. Again, the typical development timelines are several years. Therefore, is there a hope for a drug to come rapidly to the market? A strategy that is promising in the current situation is drug repurposing. Drug repurposing aims to discover novel indication areas for already approved drugs.[@bib4] The overwhelming advantage of drug repurposing is the potential for much faster market approval because of the already extensive knowledge of the drug's behavior in humans.

An expert opinion on the potential for repurposing existing antiviral agents to treat COVID-19, some of which are already clinically evaluated, was recently given.[@bib5] Here, we discuss molecular targets of the SARS-CoV-2, some of the known small molecules, and the potential for repurposing existing drugs.

Molecular Biology and Targets {#sec2}
=============================

Despite the rather large size of the RNA virus genome of \~30,000 bases, the SARS-CoV-2 genome encodes for few proteins ([Figure 1](#fig1){ref-type="fig"} ): the structural spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and the envelope (E) protein, which are needed to produce a structurally complete viral particle. Additionally, the SARS-CoV-2 genome encodes 16--17 non-structural proteins (ns1 to ns17), such as 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), helicase, and RNA-dependent RNA polymerase (RdRp).Figure 1Scheme of SARS-CoV-2 and Some of Its Molecular Protein Targets

3CLpro {#sec2.1}
------

Both the virus-encoded proteases 3CLpro and PLpro are involved in the processing of the two viral polyproteins in a coordinated manner, and thus comprise important drug targets. The structure, function, and inhibition of CoV 3CLpro (also called Mpro) has been recently comprehensively reviewed.[@bib6] The 3CLpro is a cysteine protease that cleaves and processes the viral polyproteins.

SARS-CoV-2 and SARS-CoV share 96% sequence identity in their 3CLpro. On the basis of the rapidly published virus sequence data, a homology model was created.[@bib7] Moreover, an X-ray structure of the C3Lpro covalently bound to a peptidomimetic acrylester (**1**) is now available ([Figure 2](#fig2){ref-type="fig"} , PDB ID [6LU7](pdb:6LU7){#intref0010}).[@bib8] Figure 23D Structure of SARS-CoV-2 3CLpro Bound to a Covalent Peptidomimetic Inhibitor (PDB: [6LU7](pdb:6LU7){#intref0020})The active-site Cys145 is indicated as yellow surface.

Because of the high sequence similarity of different CoV 3CLpros, a lot of previously described inhibitors can be considered to be of great use in the current SARS-CoV-2. A majority of inhibitors of the 3CLpro are covalent in nature, binding to the active-site cysteine ([Scheme 1](#sch1){ref-type="fig"} ). Different electrophilic warheads are known, including α-halocarbonyl, acrylamides, sulfonyl chlorides, aldehydes (**2**),[@bib9] isatines (**3**),[@bib10] or α-ketoheteraromates (**4**).[@bib6] Many of the molecules are rather large and are based on extensive amide chemistry, mimicking part of the peptide substrate of the protease. Moreover, their selectivity toward other potential targets in the human body has not been established.Scheme 1Selected Classes of 3CLpro InhibitorsWarheads interacting covalently with the active-site Cys145 are indicated in red.

Interestingly, some compounds binding to the active site of the 3CLpro---using a noncovalent mechanism---have been established. A high-throughput screening (HTS) identified pyrazolidinone (**5**), which displayed 1,3,5-triaryl substitution patterns, as SARS-CoV 3CLpro inhibitors.[@bib11] Nitroanilides (**6**), derived from the drug niclosamide were also found to inhibit 3CLpro.[@bib12] α-aminoacylamides were identified by an HTS, and a strong stereochemical effect was noted. The simple one-pot accessible scaffold by an Ugi-four component condensation was the key to rapidly generate structure activity relationship (SAR) for the putative P2-P1 and P1 subgroups. An optimized version ML188 (**7**) was designated as the probe status ([Figure 3](#fig3){ref-type="fig"} ). A P3 truncated version of **8** allowing for significant molecular weight (MW) reduction without diminishing potency was developed as a second probe ML300 (**9**) with potent enzyme inhibition and cellular activity. These compounds comprise rare examples of a noncovalent SARS-CoV 3CLpro inhibitor of moderate MW with good enzyme and antiviral inhibitory activity. However, these molecules suffer from extensive metabolism and rapid clearance. Nonetheless, they are a promising starting point for further drug development.[@bib13] Figure 3Non-covalent Probes Binding to the Active Site of the 3CLproAbove: co-crystal structure of probe ML188 bound to SARS-CoV (PDB: [3V3M](pdb:3V3M){#intref0025}). The homology and the 3D structural similarity of SARS-CoV (green graphic) and SARS-CoV-2 (pink graphic) 3CLpro are very high. Shown is a close up view into the ML188-binding site (cyan sticks). Shown on at the bottom is synthesis and some molecular, drug metabolism and pharmacokinetic (DMPK), and pharmacology data of the probes ML188 and ML300.

Even if such compounds cannot be rapidly developed to cope with the current situation, their development is highly warranted to be prepared for likely future CoV outbreaks. It is noteworthy that different computational approaches, including machine learning, have been published to propose approved drugs potentially binding to 3CLpro (drug repurposing).[@bib14] ^,^ [@bib15] One such approach virtually screened commercial medicines in the DrugBank database for binding into the active site of Mpro.[@bib16] Ten different commercial medicines were proposed that might form hydrogen bonds to key residues within the binding pocket of SARS-CoV-2 3CLpro, which might have higher mutation tolerance than lopinavir or ritonavir.

Flavonoids (**10**--**14**) are plant-derived natural products with diverse reported biological activities, and they have been shown to be also able to inhibit the 3CLpro ([Figure 4](#fig4){ref-type="fig"} ).[@bib17] ^,^ [@bib18] The broad-spectrum and established use of plant-based medicines to combat infectious diseases in TCM is the basis of several currently ongoing clinical trials in China. One of the largest among them assesses shuanghuanglian, a Chinese herbal medicine that contains extracts from the dried fruit lianqiao (*Forsythiae fructus*), which is purported to have been used for treating infections for more than 2,000 years.Figure 4Flavonoids Inhibiting 3CLPro as They Occur in Liang Quiao, the Seeds of the *Forsythiae fructus* Plant Used in the TCM Shuanghuanglian

Several approved HIV protease inhibitors (**15**, **16**, and **18**) were previously repurposed for the treatment of SARS ([Scheme 2](#sch2){ref-type="fig"} ).[@bib19], [@bib20], [@bib21] They were hypothesized to inhibit the SARS-CoV 3Clpro: HIV protease is a Asp protease and differs considerably from the Cys protease 3Clpro, but it also shares some common elements, such as a tetrahedral transition state and receptor pockets to recognize the amino acid side chains of the substrates. Given that SARS-CoV-2 and SARS-CoV share very high identical sequence in their 3CLpro, these HIV protease inhibitors are currently again repurposed for the treatment of COVID-19 (Chinese Clinical Trial Registry: ChiCTR2000029539).[@bib22], [@bib23], [@bib24] Scheme 2Structures of Approved HIV Drugs (**15**, **16**, **17,** and **18**) Currently Repurposed for the Treatment of COVID-19

PLpro {#sec2.2}
-----

The coronaviral PLpro is another attractive antiviral drug target because it is essential for CoV replication. The structure, function, and inhibition of the SARS-CoV PLpro has been extensively reviewed.[@bib25] Although the primary function of PLpro and 3CLpro is to process the viral polyprotein in a coordinated manner, PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to help CoV to evade the host innate immune responses. Therefore, it was recently argued that targeting PLpro with antiviral drugs might have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that might lead to cell death in surrounding, uninfected cells.[@bib25] Different compounds forming a covalent bond to the active-site Cys112 have been described, including epoxyketones, α-halo-ketones, alkynes, aldehydes, trifluoromethyl ketones, α,β-unsaturated ketone, activated esters, or vinyl sulfones.

Disulfiram (**19**), an approved drug for the treatment of chronic alcohol dependence, has a great potential for drug repurposing because it has been shown to inhibit PLpro of MERS-CoV and SARS-CoV.[@bib26] The antimetabolites 6-mercaptopurine (**20**) and 6-thioguanine (**21**) are additional drugs inhibiting PLpro ([Scheme 3](#sch3){ref-type="fig"} ).Scheme 3Structure of Approved Drugs Inhibiting the PLpro

Potent naphthyl methylamine hits (e.g., **22**) which have been structurally characterized and have been subsequently optimized toward better metabolic stability were identified from an HTS campaign,[@bib27]. (**23**)[@bib28] The naphthyl methylamines work through a noncovalent mechanism and show a rather drug-like appearance ([Figure 5](#fig5){ref-type="fig"} ).Figure 5Structural Interaction of a Non-covalent Napthylamine Inhibitor with PLproCo-crystal structure of HTS hit **22** (cyan sticks) with PLpro (gray sticks, PDB: [3MJ5](pdb:3MJ5){#intref0030}) showing some key interaction to Tyr269 forming a hydrogen bond and a T-shaped pi stacking interaction with the naphthyl moiety 2D structures, biological activity, and half-lives of **22** and **23**.[@bib29]

Spike Glycoprotein {#sec2.3}
------------------

The envelope-anchored S protein mediates CoV entry into host cells by first binding to a host receptor and then fusing viral and host membranes. The SARS-CoV-2 S protein was solved by cryoelectron microscopy and just released;[@bib30] knowing the Å-resolution structure of the SARS-CoV-2 spike will allow for additional protein engineering efforts that could improve antigenicity and protein expression for vaccine development. Moreover, the Å-resolution detail will enable the design and screening of small molecules with fusion-inhibiting potential.

It is the affinity between the viral receptor-binding domain (RBD) and the host receptor in the initial viral attachment step that primarily determines which host is susceptible to SARS-CoV infection. The SARS-CoV-2 entry through receptor binding was elucidated independently by several groups.[@bib31] ^,^ [@bib32] On the basis of the rich knowledge about SARS-CoV and the sequence homology, it was suggested that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as its receptor ([Figure 6](#fig6){ref-type="fig"} ). It uses the SARS-CoV receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells.[@bib31] ^,^ [@bib32] The interplay of the ACE receptor in cardiovascular diseases (with the well-known drug class of ACE inhibitors) and as the docking point for SARS-CoV-2 cellular infection is a current point of intense debate and research.[@bib33] Figure 6Structure of Human SARS-CoV RBD Complexed with Human ACE2 (PDB: [2AJF](pdb:2AJF){#intref0035}) as a Model for SARS-CoV-2-ACE2 InteractionACE2 is shown in blue, the RBD of SARS is in gray, and RBM of SARS-CoV is in magenta. The closeup highlights specific hydrogen bindings of a Tyr cluster of SARS-CoV in cyan.

It was found that several critical residues in SARS-CoV-2 RBM (particularly Gln493) provide favorable interactions with human ACE2, consistent with SARS-CoV-2's capacity for human cell infection.

On the basis of the extensive modeling of the virus-human receptor interactions, it was also predicted that a single N501T mutation might significantly enhance the binding affinity between SARS-CoV-2 RBD and human ACE2 and thus potentially lead to much more virulent bodies.[@bib31] ^,^ [@bib32] The emergency and evolution of novel mutations at the 501 position in SARS-CoV-2-infected and Covid-19 patients have to be closely monitored.[@bib34]

Mutations in the S protein are the ones causing the zoonosis, and as a result, not all of them will lead to their binding to ACE2. Therefore, drugs targeting the S protein-ACE2 interaction might not apply to some of the future CoVs. On the other hand, the spike-shaped protein on the surface of the viruses causing SARS, MERS, and COVID-19 provides a tantalizing target for antibodies or other compounds, which could prevent CoVs from invading human cells.[@bib35] The virus' S protein seems to emerge as the consensus target antigen.

RdRp {#sec2.4}
----

The RdRp enzyme allows the viral genome to be transcribed into new RNA copies by using the host cell's machinery. RdRp inhibitors are emerging as a new strategy to fight viral infections.[@bib35] The chemistry and biology of RdRp have been extensively reviewed.[@bib36]

RNA polymerase inhibitors are promising agents to fight Covid-19.[@bib5] RdRp proteins of SARS-CoV-2 and SARS-CoV share 96% sequence identity. Favipiravir (**24**) is an approved RNA polymerase inhibitor for the treatment of the influenza pandemic. It has been shown not only to be active in influenza but also active against other RNA viruses ([Figure 7](#fig7){ref-type="fig"} ).[@bib37] Favipiravir is a prodrug, which is metabolized in cells into the active purine-mimicking nucleotide favipiravir-ribofuranosyl-5-triphosphate that inhibits the RNA replication and thus the viral progression.[@bib38] Interestingly, it does not inhibit host DNA and RNA synthesis and inosine 5′-monophosphate dehydrogenase (IMPDH) activity. Favipiravir reportedly demonstrated efficacy with minor side effects in an ongoing 70-patient clinical trial in Shenzhen, Guangdong province.[@bib5] The drug's generic version received approval by the health authorities in China.[@bib39] Figure 7Structures of Four Promising Drugs for Covid-19 Treatment and an Aristeromycin DerivativeFavipiravir **24** is now the first approved drug to treat Covid-19

The broad-spectrum antiviral drug remdesivir together with chloroquine effectively inhibit the recently emerged novel CoV (SARS-CoV-2) *in vitro*.[@bib40] ^,^ [@bib41] Remdesivir (**25**) reduced SARS-CoV-2 infection of monkey kidney cells with an EC~50~ of 0.77 μM. The compound is in late-stage clinical development and has been recently described to inhibit multiple RNA viruses on a cellular level, including Ebola and SARS. The presumed mode of action of the adenosine analog prodrug remdesivir is pre-mature RNA synthesis termination by incorporation into nascent viral RNA chains.[@bib42] Galidesivir (**26**) is another antiviral drug under clinical development with potential in COVID-19 treatment ([Figure 7](#fig7){ref-type="fig"}). It is an adenosine analog and is currently developed for Ebola virus disease and Marburg virus disease. It also shows broad-spectrum antiviral activity against RNA virus families including CoVs.[@bib43]

Multiple other RdRp inhibitors are described in the literature, for example, broad-spectrum antiviral 6′-bis fluorinated aristeromycin analog (**27**).[@bib44]

Chloroquine (**28**) is an existing anti-malaria medicine also used to treat several other diseases. It blocked virus infection with an EC~50~ of 1.13 μM.[@bib40] ^,^ [@bib41] Its mode of action is unclear. However, chloroquine inhibits endosomal acidification and thus could stop the release of viral DNA into the cytoplasm. It is under assessment in more than 100 patients at over ten hospitals in Beijing and Guangdong province. Plans for an additional study in Hunan province are underway.

Other Viral Proteins {#sec2.5}
--------------------

The role of the other SARS-CoV-2 N proteins as drug-discovery targets is less clear. For the assembly of the replication and/or transcription complexes, there is a vast interaction network described between the non-structural proteins. Similarly, viral particle assembly requires orchestrated interaction between N, S, M, and E proteins. All these interactions can be potential targets, but the structural information is currently minimal. Resolution of the protein and complex structures will provide new unique drug targets. For example, the crystal structure of SARS-CoV-2 N protein RNA-binding domain was just published and will give structural insight as a potential drug target.[@bib45] It is rapidly detected by antibodies in serum, plasma, and peripheral blood, and might therefore serve to develop specific diagnostics.

Host Targets {#sec2.6}
------------

Using methods of machine learning-enabled scientific literature analysis, the biotech company BenevolentAI proposed the AP2-associated protein kinase 1 (AAK1) as a host target to fight SARS-CoV-2. AAK1 is the key enzyme of receptor-mediated endocytosis, which is the major mechanism of most viruses to enter their host cells. Thus, they predict the approved (for rheumatoid arthritis) kinase inhibitor baricitinib **29** to reduce the ability of the virus to infect lung cells ([Figure 8](#fig8){ref-type="fig"} ).[@bib46] Figure 8BenevolentAI Knowledge Graph on SARS-CoV-2 and Approved Kinase Inhibitor Baricitinib **29**

Outlook {#sec3}
=======

The recent emergence of the Wuhan CoV (SARS-CoV-2) has put the world on alert. The rapid worldwide spread and the high human-to-human transmissibility, combined with the inability to contain the pandemic, is causing an increasing death toll and also considerable paralysis of the world economy. The COVID-19 could decrease and disappear or could be established worldwide in the human population and reoccur seasonally in future mutations through zoonosis from one of the animal reservoirs. However, it is very likely that in the upcoming years, we will see more outbreaks from CoV and other viruses. The basic, translational, and public health research communities have to prepare for this much better. The outbreak has emphasized the urgent need for renewed efforts to develop broad-spectrum antiviral agents to combat CoVs. On the positive side, much new information of the virus biology and the spread was immediately shared, whereas, on the negative side, many past opportunities to develop antivirals against CoVs were not taken, despite a large number of promising approaches and compounds.[@bib47] The past decade has shown that CoV outbreaks are regularly reoccurring with more or less health effect on human and livestock. It remains to be hoped that the current pandemic will slow down and end as predicted in summer. Furthermore, it turns out that containment measures are not effective to avoid more severe spread. It remains to be seen whether efficient and long-lasting immunity will develop in the infected population with regard to future outbreaks and whether pharmacological measures can be rapidly developed to be able to treat severely sick people.
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